Price
$1.33
Increased by +1.53%
Dollar Volume (20D)
397.17 K
ADR%
4.47
Earnings Report Date (estimate)
Mar 21, 24
Shares Float
29.35 M
Shares Outstanding
44.66 M
Shares Short
126.49 K
Market Cap.
58.5 M
Beta
1.27
Price / Earnings
N/A
20D Range
1.19 1.36
50D Range
1.01 1.52
200D Range
0.57 1.7
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 9, 23 -0.44
Increased by +15.38%
-0.28
Decreased by -57.14%
Aug 10, 23 -0.37
Increased by +42.19%
-0.07
Decreased by -428.57%
May 11, 23 -0.57
Increased by +16.18%
-0.55
Decreased by -3.64%
Mar 23, 23 -0.57
Increased by +12.31%
-0.49
Decreased by -16.33%
Nov 8, 22 -0.52
Increased by +30.67%
-0.55
Increased by +5.45%
Aug 9, 22 -0.64
Increased by +13.51%
-0.57
Decreased by -12.28%
May 10, 22 -0.68
Decreased by -4.62%
-0.59
Decreased by -15.25%
Mar 17, 22 -0.65
Increased by +10.96%
-0.74
Increased by +12.16%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 0
Decreased by N/A%
-21.58 M
Increased by +5.54%
Decreased by N/A%
Decreased by N/A%
Jun 30, 23 0
Decreased by N/A%
67.48 M
Increased by +338.14%
Increased by +N/A%
Decreased by N/A%
Mar 31, 23 0
Decreased by N/A%
-24.12 M
Increased by +20.27%
Decreased by N/A%
Decreased by N/A%
Dec 31, 22 0
Decreased by N/A%
32.57 M
Increased by +215.38%
Increased by +N/A%
Decreased by N/A%
Sep 30, 22 0
Decreased by N/A%
-22.84 M
Increased by +29.96%
Decreased by N/A%
Decreased by N/A%
Jun 30, 22 0
Decreased by N/A%
-28.33 M
Increased by +9.73%
Decreased by N/A%
Decreased by N/A%
Mar 31, 22 0
Decreased by N/A%
-30.25 M
Decreased by -12.45%
Decreased by N/A%
Decreased by N/A%
Dec 31, 21 0
Decreased by N/A%
-28.23 M
Decreased by -0.34%
Decreased by N/A%
Decreased by N/A%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

AVROBIO, Inc., a clinical-stage gene therapy company, develops ex vivo lentiviral-based gene therapies to treat rare diseases following a single dose worldwide. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1, as well as to treat Gaucher disease type 3; AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease; AVR-RD-04, which is in phase 1/2 clinical trial for the treatment of cystinosis; and AVR-RD-05 that is in preclinical stage for the treatment of Hunter syndrome. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.